Archived Monthly Oncology Tumor Boards (July 2016 - June 2017)

NCCN is offering a series of twelve multidisciplinary case-based webinars on a variety of topics: bladder cancer, breast cancer, colorectal cancer, kidney cancer, lung cancer, melanoma, multiple myeloma, myelofibrosis, ovarian cancer, peripheral T-cell lymphomas, prostate cancer, and sarcoma. Each webinar will be facilitated by at least two faculty members. A different topic will be presented each month for twelve months (July 2016 until June 2017). The goal of this series is to ensure that members of a multidisciplinary team, including physicians, nurses, pharmacists and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with various cancer types.

The NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®) are a set of step-by-step evidence-based, consensus-driven recommendations that ensure that patients receive preventive, diagnostic treatment, and care that is most likely to lead to optimal outcomes. The NCCN recommendations are applicable to about 95% of patients. Clinicians need to consider the current clinical status of the patient, including general health, disease specifics, concomitant conditions, current and previous therapies, and the patients how to best apply appropriate standard of care including identifying circumstances where appropriate management requires adapting the NCCN Guidelines to the needs of the individual. This activity series will discuss the specific recommendations in the NCCN Guidelines as well as unique patient circumstances that impact how the NCCN Guidelines might be best applied.

Target Audience

These educational programs are designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.

Additional information
Supporters: 

This educational activity is supported by educational grants from Astellas; AstraZeneca; Celgene Corporation; Eisai; Genomic Health, Inc.; Janssen Biotech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Sanofi-Genzyme; and Takeda Oncology. This activity is supported by educational funding provided by Amgen. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This educational activity is supported by an unrestricted education grant from Exelixis, Inc. This educational activity is supported by an independent educational grant from Merck.

Course summary
Course opens: 
07/21/2016
Course expires: 
06/15/2018
Cost:
$0.00

These educational programs have been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals. Complete accreditation information is provided before each individual educational activity.

Available Credit

Accreditation Period

Course opens: 
07/21/2016
Course expires: 
06/15/2018
 
Status
Price
Title
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.

Price

Cost:
$0.00
Please login or register to take this course.